Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | From cold tumors to hot targets: immunotherapy advances in sarcoma treatment

Javier Martin-Broto, MD, PhD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, discusses the nuanced role of immunotherapy in sarcomas. While most sarcomas are characterized by a low tumor mutation burden (~2 mutations/Mb) and a cold tumor microenvironment, select subtypes exhibit notable immunosensitivity. Alveolar soft part sarcoma (ASPS), for example, responds well to anti-PD-1 agents like tislelizumab, despite lacking classical biomarkers of response. Emerging data on immunogenic cell death, particularly with doxorubicin in leiomyosarcoma and undifferentiated pleomorphic sarcoma, support combination strategies with checkpoint inhibitors. Additionally, TCR-T cell therapy is showing promise in synovial sarcoma and myxofibrosarcoma. These findings highlight immunotherapy’s evolving niche within sarcoma treatment paradigms. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.